Acceleron Pharma Inc (XLRN)

25.25
NASDAQ : Health Care
Prev Close 26.45
Day Low/High 25.14 / 26.39
52 Wk Low/High 23.07 / 41.69
Avg Volume 407.10K
Exchange NASDAQ
Shares Outstanding 38.62M
Market Cap 1.02B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Luspatercept Phase 2 Data Presented At The 14th International Symposium On Myelodysplastic Syndromes

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...

Acceleron Announces Management Change

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics As Head Of Biologics

Dr. Grinberg, senior scientist with 12 years of biotech industry experience in biologics discovery and development, joins Dragonfly's team to accelerate development of its novel Natural Killer cell-based immunotherapies.

Acceleron To Participate In Two Healthcare Investor Conferences In May

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Acceleron Provides Clinical Development Updates On Luspatercept Program

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Acceleron To Host Webcast To Review First Quarter 2017 Financial And Operational Results On May 8, 2017

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces Clinical Presentations On Luspatercept At The 14th International Symposium On Myelodysplastic Syndromes

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces Plans To Initiate A Phase 2 Trial Of ACE-083 In Charcot-Marie-Tooth Neuromuscular Disease And Host Educational Webinar

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma Price Target Raised by Leerink

Acceleron Pharma Price Target Raised by Leerink

The company reported a fourth quarter loss on Wednesday.

Acceleron Reports Fourth Quarter And Year Ended 2016 Operational And Financial Results

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a...

Acceleron To Participate In Two Healthcare Investor Conferences In March

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma To Webcast Conference Call Of Fourth Quarter And Year Ended 2016 Financial Results On March 1, 2017

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron To Participate In Two Healthcare Investor Conferences In February

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Acceleron Pharma Enters Oversold Territory (XLRN)

Acceleron Pharma Enters Oversold Territory (XLRN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acceleron Outlines Corporate Goals And Priorities For 2017

Acceleron Outlines Corporate Goals And Priorities For 2017

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced its...

Acceleron To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference

Acceleron To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces First Patient Treated In Phase 2 Trial Of ACE-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Announces First Patient Treated In Phase 2 Trial Of ACE-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

There's little to substantiate the president-elect's claim that he will bring drug prices down, but biotech investors are trading anyway.

Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ: XLRN) and Celgene Corporation (NASDAQ: CELG) today announced Phase 2 results from an open-label three-month base study and the ongoing long-term safety extension study with luspatercept in...

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with...

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.

Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...

Acceleron Pharma To Host Conference Call And Webcast To Review Data Presented At The 58th American Society Of Hematology Annual Meeting And Exposition

Acceleron Pharma To Host Conference Call And Webcast To Review Data Presented At The 58th American Society Of Hematology Annual Meeting And Exposition

Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma Reports Third Quarter 2016 Financial And Operational Results

Acceleron Pharma Reports Third Quarter 2016 Financial And Operational Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a...

RSI Alert: Acceleron Pharma (XLRN) Now Oversold

RSI Alert: Acceleron Pharma (XLRN) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acceleron Announces New Data Presentations At The 58th American Society Of Hematology Annual Meeting And Exposition

Acceleron Announces New Data Presentations At The 58th American Society Of Hematology Annual Meeting And Exposition

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...